About the authors:
Claire Devine is a patent attorney at Appleyard Lees. Claire has worked with a range of clients in the biotechnology and pharmaceutical areas, on applications related to a broad range of technologies, including antibodies, industrial biotechnology, gene therapies, RNA therapies, new chemical entities and drug repurposing.
Barbara Fleck is a partner and patent attorney at Appleyard Lees. Her work includes a wide range of technologies in the biotechnology and pharmaceutical areas, with a specialist in-depth knowledge in the fields of antibody therapeutics and agrisciences.
In a recent article in Intellectual Property Magazine, patent attorneys Calire Devine and Barbara Fleck discussed the importance of early planning in cell and gene IP strategy.
